Wund(er)heilung mit Amnion – DGFG erhält deutschen Wundpreis 2021
Ausschreibung DGNI-Pflege- und Therapiepreis 2022
Ausschreibung: Otsuka Team Award Psychiatry+ 2021
BGW-Gesundheitspreis 2022: Gute Praxis aus der Altenpflege gesucht!
Aktionsbündnis Patientensicherheit vergibt Deutschen Preis für Patientensicherheit 2021 an herausragende…
8.-10. September 2021: Weimar Sepsis Update 2021 – Beyond the…
13.09. – 18.09.2021: Viszeralmedizin 2021
24.06. – 26.06.2021: 27. Jahrestagung der Deutschen Gesellschaft für Radioonkologie
17.06. – 19.06.2021: 47. Jahrestagung der Gesellschaft für Neonatologie und…
16. bis 18. Juni 2021: Deutscher Kongress für Psychosomatische Medizin…
Novartis Vaccines and Diagnostics S.r.l. withdraws its application for paediatric use marketing authorisation for Fluad Paediatric (influenza vaccine)
London, UK (February 16, 2012) – The European Medicines Agency has been formally notified by Novartis Vaccines and Diagnostics S.r.l. of its decision to withdraw its application for a paediatric-use marketing authorisation (PUMA) for the medicine Fluad Paediatric (influenza vaccine, surface antigen, inactivated, adjuvanted with MF59C.1).
Fluad Paediatric was intended to be used for the active immunisation against influenza in infants and young children.
The application for the paediatric-use marketing authorisation for Fluad Paediatric was initially submitted to the Agency on 13 December 2010. At the time of the withdrawal it was under evaluation by the Committee for Medicinal Products for Human Use (CHMP).
In its official letter, the company stated that its decision to withdraw the application is based on the fact that it is unable to address the questions of the Committee within the required timelines.
More information about Fluad Paediatric and the stage of the scientific assessment procedure at the time of withdrawal will be made available in a question-and-answer document. This document, together with the withdrawal letter from the company, will be published on the Agency’s website after the CHMP meeting on 13-16 February 2012.
Withdrawal of an application does not prejudice the possibility of a company making a new application at a later stage.
European Medicines Agency, 16.02.2012 (tB).